The association between obstructive sleep apnea and lung nodule, carcinoembryonic antigen

Li-Da Chen¹ · Ai-Ming Zeng² · Jie-Feng Huang² · Meng-Xue Chen² · Gong-Ping Chen²,³,⁴ · Qi-Chang Lin²,³,⁴

Received: 10 September 2022 / Accepted: 1 December 2022 / Published online: 9 December 2022
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abstract
Purpose The association between obstructive sleep apnea (OSA) and cancer risks gaining more and more attention. Data on the association between OSA and lung cancer risk are limited. This study is to investigate whether a link exists between low-dose computed tomography (LDCT) scanning of the chest findings, carcinoembryonic antigen (CEA) and OSA in patients suspected of OSA.

Methods The cross-sectional study included patients aged 18 years or older who underwent continuous nocturnal polysomnography at our sleep center between February 2019 and November 2020. All subjects underwent chest LDCT and CEA. Patients with an apnea–hypopnea index (AHI) of ≥ 15/h were classified as clinically significant OSA group, whereas patients with an AHI < 15/h were classified as control group.

Results A total of 277 patients were enrolled in the study. 176 patients were categorized into the OSA group, while 101 patients were categorized into the control group. There is no relationship between any OSA-related parameter and presence of lung nodule or presence of ≥ 6 mm lung nodule in the binary logistic regression analysis. OSA group demonstrated a significant higher value of CEA than control group. Stepwise multiple linear regression analysis showed that lowest O₂ saturation ($\beta = -0.256, p < 0.001$), smoking status ($\beta = 0.156, p = 0.007$) and age ($\beta = 0.153, p = 0.008$) were independent predictors of elevated CEA.

Conclusions OSA was independently related to the elevated of serum CEA level, but not with presence of pulmonary nodule or ≥ 6 mm pulmonary nodule in LDCT. Further well-designed longitudinal studies with pathology available are needed to identify the association between OSA and risk of lung cancer.

Keywords Obstructive sleep apnea · Lung nodules · Carcinoembryonic antigen · Lung cancer

Introduction
Obstructive sleep apnea (OSA), the most common form of sleep-disordered breathing (SDB), is mainly characterized by recurrent episodes of partial or complete upper airway obstructions during sleep that lead to intermittent hypoxia and sleep fragmentation. OSA is known to exert pathophysiologic and molecular disturbances on multiple organs and is linked to a variety of poor health outcomes. Recent evidences suggested that OSA was associated with increased incidence and mortality of cancer, especially in melanoma, lung cancer, prostate cancer, and colorectal cancer [1–4]. However, some studies opposed the results and indicated that OSA was not independently associated with cancer incidence and mortality [5]. It is not surprising that they commonly coexist in an individual as both OSA and cancer are common problems.
Lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and is the leading cause of cancer-related deaths (18.4% of the total cancer deaths) worldwide [6]. It is well known that tobacco smoking is a major risk factor for the development of lung cancer. There are several studies examining the association between OSA and the risk of lung cancer and its outcomes [7–10]. A study evaluating the prevalence of OSA in a lung cancer screening program found that OSA was very common in the high-risk population. Further multivariate analysis adjusted for confounders indicated that nocturnal hypoxemia was associated with positive screening findings (nodules > 6 mm) [11]. Another study investigating the prevalence of OSA in patients with newly diagnosed lung cancer showed a high prevalence of OSA (49%) in this population [12]. Nevertheless, the data of this issue are limited and the results remain inclusive. Furthermore, all studies focus on population with lung cancer or high risk of lung cancer. To our knowledge, there is no published study exploring this relationship based on population with OSA or clinical suspicion of OSA.

Low-dose computed tomography (LDCT) of the chest has been extensively used to screen lung cancer and shown to be efficacious at reducing mortality from lung cancer [13]. Serum tumor biomarkers can be accessed easily and economically, so they have been used as diagnostic adjunct and monitoring the course of lung cancer in the clinical setting. The National Academy of Clinical Biochemistry (NACB) recommends the serum CEA as a tumor biomarker for adjuvant lung cancer diagnosis. Hence, the present study aimed to explore the relationship between OSA and LDCT scanning of the chest finding in a cohort of patients studied for OSA suspicion. Furthermore, the association between OSA and CEA was also investigated in this study.

**Materials and methods**

**Subjects**

Consecutive patients with age > 18 years undergoing overnight polysomnography because of symptoms of sleep apnea between February 2019 and November 2020 in our sleep center were included in the study. The exclusion criteria included those patients with known diagnosis of OSA and receiving any OSA-related therapies, patients with known diagnosis of any malignancy and receiving any tumor-related therapies, patients with serious comorbidities, such as acute myocardial infarction. Pregnancy was also excluded. The informed consents were signed by all parents. This study was reviewed and approved by ethics committee of the First Affiliated Hospital of Fujian Medical University (2020-422).

**Anthropometric measurements and polysomnography**

A detailed baseline evaluation including age, smoking habits, alcohol consumption, snoring, witnessed apneas, other medical history, and medication use were performed. Excessive daytime sleepiness was evaluated by the Epworth Sleepiness Scale. Body weight and height were measured in bare feet and light clothing in the morning by the same person using the same equipment. Body mass index (BMI) was calculated by dividing body weight by height squared (kg/m²). Waist circumference (WC) was measured at the level midway between the lower costal margin and the iliac crest. Neck circumference (NC) was measured at the level of the laryngeal prominence. A full-night polysomnography (P Series Sleep System, Compumedics, Melbourne, Australia) was performed for every participant at the sleep center. All of the PSG data were visually scored by trained technicians according to standardized criteria [14]. Details have been described in our previous study [15]. The existing literature shows that there is a significant dose–response effect between AHI and the risk of cancer death; therefore, patients with an apnea–hypopnea index (AHI) higher than or equal to 15/h were categorized as having clinically significant OSA. Patients with an AHI less than 15/h were categorized into control group [16, 17].

**Blood samples**

A fasting blood sample was drawn after a full night sleep study and then centrifuged at 3000 rpm for 10 min. CEA was quantitatively measured using electrochemiluminescence immunoassay (ECLIA) assay kits, according to the manufacturer's instructions (Cobas, Roche Diagnostics, Germany).

**LDCT of the chest**

All subjects were examined using a multilayer helical scanner at a low-dose project (105 mA, 120 kV, 2 mm overlapping sections). LDCT examination was performed in a single breath hold during complete inhalation. Chest CT image uploaded to Picture Archiving and Communication Systems (PACS). An experienced radiologist distinguished and described pulmonary nodules based on their size, presence, and type (solid, nonsolid, or partially solid) and the location of the nodules. It was reviewed by another senior radiologist. Pulmonary nodules was represented by the average the maximum nodule diameter and the nodule diameter perpendicular to this maximum.
Statistical analysis

The SPSS 19.0 package (SPSS Inc, Chicago, IL, USA) was used for the statistical analysis. GraphPad Prism 8 (GraphPad Software, USA) was used to draw the graphs. Normal distribution tests were performed on the data prior to analysis. In the case of normal distribution, the Student’s t test was used to compare the means between two groups, or in the case of non-normal distribution, the Mann–Whitney U test was used for non-parametric data. Where appropriate, the categorical variables were compared using chi-square test or Fisher exact test. Binary logistic regression was used to analyze the relationship between OSA-related parameters and presence of pulmonary nodule, ≥ 6 mm pulmonary nodule. Correlations between variables were explored using the Pearson correlation test. Multiple linear regression was used to determine the independent predictors of CEA. When p value was less than 0.05, it was considered statistically significant.

Results

Comparison of variables of all patients

The study group comprised 277 patients with 206 male and 71 female. The mean age was 53.49 ± 12.71 years, mean BMI was 27.34 ± 4.77 kg/m², mean AHI was 28.89 ± 21.82. 101 patients with AHI < 15/h were categorized into control group, the remaining 176 patients with AHI ≥ 15/h were categorized into OSA group. Table 1 shows the comparison of baseline variables of OSA and controls. There were no significant differences in age, prevalence of diabetes, COPD, emphysema, smoking status, alcohol consumption between groups. The male sex ratio, prevalence of hypertension, dyslipidemia, BMI, NC, WC, AHI, oxygen desaturation index (ODI), the percentage of sleep time with SpO2 (T90%), Epworth Sleepiness Scale (ESS) score of OSA group were significantly higher

| Subjects n | Controls | OSA | p values |
|-----------|----------|-----|---------|
| Age, years | 101      | 176  | 0.389   |
| Male sex, number (%) | 52.57 ± 14.10 | 54.01 ± 11.85 | 0.020   |
| Hypertension, number (%) | 67 (66.3) | 139 (79.0) | <0.001  |
| Diabetes, number (%) | 38 (37.6) | 108 (61.4) | <0.001  |
| Dyslipidemia, number (%) | 19 (18.8) | 33 (18.8) | 0.990   |
| COPD, number (%) | 6 (5.9) | 30 (17.0) | 0.008   |
| Emphysema, number (%) | 4 (4.0) | 4 (2.3) | 0.420   |
| Tobacco status | 2 (2.0) | 2 (1.1) | 0.624   |
| Never, number (%) | 69 (68.3) | 102 (58.0) | 0.113   |
| Former, number (%) | 14 (13.9) | 23 (13.1) | 0.776   |
| Active, number (%) | 18 (17.8) | 51 (29.0) | 0.072   |
| Alcohol consumption, number (%) | 24 (23.8) | 60 (34.1) | <0.001  |
| BMI (kg/m²) | 25.67 ± 4.23 | 28.29 ± 4.80 | <0.001  |
| NC (cm) | 37.30 ± 3.20 | 39.75 ± 3.77 | <0.001  |
| WC (cm) | 93.75 ± 12.25 | 101.31 ± 11.80 | <0.001  |
| AHI | 8.14 (4.80–11.20) | 37.70 (26.40–51.05) | <0.001  |
| ODI | 5.70 (2.80–8.20) | 28.60 (18.38–46.70) | <0.001  |
| T90% (%) | 0.14 (0.02–0.47) | 3.37 (0.74–10.76) | <0.001  |
| LaSO₂ (%) | 85.00 (82.00–88.00) | 76.50 (65.00–82.00) | <0.001  |
| Average SpO₂ (%) | 95.00 (94.00–96.00) | 93.00 (91.00–94.00) | <0.001  |
| ESS score | 5.92 ± 4.48 | 8.65 ± 5.89 | <0.001  |
| Nodule, number (%) | 51 (50.5) | 92 (52.3) | 0.776   |
| Nodules ≥ 6 mm, number (%) | 19 (18.8) | 21 (11.9) | 0.117   |

Normally distributed data were expressed as mean ± SD, skewed data (including AHI, ODI, T90%, LaSO₂, Average SaO₂) were presented as median (interquartile range). Categorical variables were expressed as number (percentage). OSA: obstructive sleep apnea, COPD: chronic obstructive pulmonary diseases, BMI: body mass index, NC: neck circumference, WC: waist circumference, AHI: apnea–hypopnea index, ODI: oxygen desaturation index, T90%: the percentage of sleep time with SpO₂, LaSO₂: lowest O₂ saturation, ESS: Epworth Sleepiness Scale

Table 1 Comparison of variables of OSA and controls
than control group. The OSA patients had significantly lower LaSO₂, average SpO₂ compared with patients in control group. No significant differences were observed in presence of lung nodule and presence of lung nodule ≥ 6 mm between groups.

Comparison of variables of patients with lung nodules.

Out of 277 patients included, 143 patients with lung nodules were further analyzed. They were also divided into control group and OSA group. The detailed information is shown in Table 2. Similar to the results yielded from whole population, the prevalence of hypertension, dyslipidemia, BMI, NC, WC, sleep parameters and ESS score were significantly different between OSA and control group. There was no statistical difference in the prevalence of multiple pulmonary nodules, ground-glass opacity, nodule size or presence of lung nodule ≥ 6 mm between groups.

**Table 2** Comparison of variables of OSA and controls in patients with lung nodules

| Subjects n | Controls | OSA | p values |
|------------|----------|-----|----------|
| Age, years | 5.24 ± 14.50 | 55.51 ± 12.36 | 0.905 |
| Male sex, number (%) | 32 (62.7) | 69 (75.0) | 0.123 |
| Hypertension, number (%) | 14 (27.5) | 59 (64.1) | 0.000 |
| Diabetes, number (%) | 8 (15.7) | 21 (22.8) | 0.309 |
| Dyslipidemia, number (%) | 1 (2.0) | 14 (15.2) | 0.013 |
| COPD, number (%) | 3 (5.9) | 2 (2.2) | 0.348 |
| Emphysema, number (%) | 0 (0.0) | 1 (1.1) | 1.000 |
| Tobacco status | | | |
| Never, number (%) | 33 (64.7) | 56 (60.9) | |
| Former, number (%) | 9 (17.6) | 13 (14.1) | |
| Active, number (%) | 9 (17.6) | 23 (25.0) | 0.567 |
| Alcohol consumption, number (%) | 17 (33.3) | 28 (30.4) | 0.721 |
| BMI (kg/m²) | 25.33 ± 4.50 | 28.17 ± 5.06 | 0.001 |
| NC (cm) | 37.01 ± 3.23 | 39.63 ± 3.78 | < 0.001 |
| WC (cm) | 94.53 ± 11.52 | 101.26 ± 13.00 | 0.020 |
| AHI | 8.90 (6.80–11.80) | 36.60 (26.25–48.35) | < 0.001 |
| ODI | 5.80 (2.70–8.90) | 27.80 (18.93–37.68) | < 0.001 |
| T90% (%) | 0.13 (0.02–0.46) | 1.88 (0.44–8.56) | < 0.001 |
| LaSO₂ (%) | 85.00 (82.00–89.00) | 76.50 (64.25–83.00) | < 0.001 |
| Average SpO₂ (%) | 95.00 (94.00–96.00) | 93.00 (91.00–94.75) | < 0.001 |
| ESS score | 5.45 ± 4.47 | 8.20 ± 6.17 | 0.003 |
| MPN | 24 (47.1) | 50 (54.3) | 0.403 |
| GGO | 6 (11.8) | 12 (13.0) | 0.825 |
| Nodule size | 0.59 ± 0.59 | 0.46 ± 0.30 | 0.075 |
| Nodules ≥ 6 mm | 19 (37.3) | 21 (22.8) | 0.066 |

Normally distributed data were expressed as mean ± SD, skewed data (including AHI, ODI, T90%) were presented as median (interquartile range). Categorical variables were expressed as number (percentage)

OSA obstructive sleep apnea, COPD chronic obstructive pulmonary diseases, BMI body mass index, NC neck circumference, WC waist circumference, AHI apnea–hypopnea index, ODI oxygen desaturation index, T90% the percentage of sleep time with SpO₂, ESS Epworth Sleepiness Scale, MPN multiple pulmonary nodules, GGO ground-glass opacity

Relationship between OSA and lung nodules

Binary logistic regression was further performed to analyze the relationship between OSA-related parameters and presence of lung nodule, ≥ 6 mm lung nodule. The results are presented in Table 3. There is no relationship between any OSA-related parameter and presence of lung nodule or presence of ≥ 6 mm lung nodule. The correlation analysis indicated that the size of lung nodule was not correlated with any OSA-related parameter (Fig. 1).

Relationship between OSA and CEA

Figure 2 shows the comparison of CEA between OSA and control group. OSA group demonstrated a significant higher value of CEA than control group (2.53 ± 1.66 vs. 2.12 ± 1.15 ng/ml). The correlation analysis revealed that age, the presence of diabetes, tobacco status, BMI, WC, AHI, ODI, T90%, LaSO₂, and...
average SpO2 were the factors correlated significantly with CEA (Table 4). Stepwise multiple linear regression was performed to determine the independent variables of CEA. Age, sex ratio, presence of hypertension, diabetes, dyslipidemia, COPD, tobacco status, alcohol consumption, BMI, WC, AHI, ODI, T90%, LaSO2, and average SpO2 were taken as independent variables entering into the regression model. The results showed that LaSO2 ($\beta = -0.256, p < 0.001$), tobacco status ($\beta = 0.156, p = 0.007$) and age ($\beta = 0.153, p = 0.008$) were independent predictors of elevated CEA.

Table 3 Univariate analysis for lung nodules

| Parameter | Presence of lung nodules | Presence of ≥ 6 mm lung nodules |
|-----------|--------------------------|--------------------------------|
|           | OR    | 95% CI  | p values | OR    | 95% CI  | p values |
| AHI       | 0.996 | 0.985–1.006 | 0.417    | 0.987 | 0.970–1.004 | 0.135    |
| ODI       | 0.993 | 0.982–1.004 | 0.191    | 0.986 | 0.969–1.004 | 0.131    |
| T90% (%)  | 0.981 | 0.960–1.002 | 0.074    | 0.969 | 0.927–1.013 | 0.160    |
| LaSO2 (%) | 1.007 | 0.988–1.026 | 0.492    | 1.014 | 0.984–1.045 | 0.353    |
| Average SpO2 (%) | 1.002 | 0.938–1.070 | 0.957    | 1.004 | 0.913–1.103 | 0.941    |

AHI: apnea–hypopnea index, ODI: oxygen desaturation index, T90%: the percentage of sleep time with SpO2, LaSO2: lowest O2 saturation, OR: odds ratio, CI: confidence interval.

Fig. 1 Correlation analysis OSA-related parameter and the size of lung nodule. OSA: obstructive sleep apnea, AHI: apnea–hypopnea index, ODI: oxygen desaturation index, T90%: the percentage of sleep time with SpO2, LaSO2: lowest O2 saturation.
Discussion

In a cohort of patients with suspicion of OSA, we demonstrated that nocturnal hypoxia was independently related to the elevated serum CEA level after adjusting confounding factors. OSA was not related with presence of pulmonary nodule or ≥ 6 mm pulmonary nodule in LDCT.

There is growing interest in evaluating the association between OSA and cancer incidence. Several large cohort studies have investigated whether OSA increased the risk of cancer. A community-based cohort study with long-term follow-up found that moderate–severe OSA was significantly associated with incident cancer after adjusting confounding factors [18]. A multicenter, clinical cohort study including 4,910 patients investigated for suspected OSA revealed that severe OSA was associated with higher incidence of cancer, especially in patients aged < 65 years and men [2]. However, some study did not support an independent relationship between OSA and cancer incidence. Over a 7.8-year follow-up of 10,149 patients, Kendzerska et al. [1] found that the severity of sleep apnea was not significantly associated with either prevalent or incident cancer after adjustment for age, sex, BMI and smoking status at baseline. A recent prospective study with 8-year follow-up of 65,330 older women showed that OSA was associated with a 15% increase in total cancer risk. The association became non-significant after adjustment for multiple cancer risk factors [19].

Lung cancer is the most commonly seen cancer. Some studies focused on the relationship between OSA and risk of lung cancer and its mortality. A study performed in Germany reported high prevalence of OSA in newly diagnosed lung cancer patients, with the incidence of moderate to severe OSA reaching 17%. However, it could not determine whether OSA affects the prevalence of lung cancer [12]. Another study performed in Spain reported that the prevalence of OSA was 80% in consecutive patients with newly diagnosed lung cancer [9]. A cross-sectional study including 302 patients for investigating relationship between OSA and lung cancer discovered that AHI and nocturnal hypoxemia did increase the incidence of lung cancer, especially in moderate and severe OSA [7]. However, data are still limited in this issue and the conclusion is controversial.

Serum tumor markers are becoming more and more important in the diagnosis and staging of malignant tumors. CEA is one of the most commonly used tumor markers. Its overexpression is first found in colorectal cancer, and then in respiratory tract and other organs. Although the use of CEA in patients with lung cancer is still controversial, its low cost and easy availability make it a relatively reliable indicator of lung cancer. CEA is essentially a marker of adenocarcinoma, while it is closely related to TNM stage and tumor aggressiveness, so it has become an indicator of lung adenocarcinoma prognosis.

The mechanisms likely to be involved in the association between OSA and cancer included systemic inflammation, oxidative stress, angiogenesis, immune dysfunction. In an animal study, Almendros et al. [20] demonstrated that mice exposed to intermittent–hypoxia (IH) exhibited accelerated tumor growth and presented more tumor invasion. Tumor-associated macrophages from IH-exposed mice significantly increased TC1 migration and extravasation compared with normoxia group. Another animal study also confirmed that IH markedly enhanced the number and weight of lung metastatic colonies in mouse. Compared with control group, Lung tissues with tumor metastasis from IH group showed increased oxidative stress, as assessed by p22phox and...
superoxide dismutase (SOD) mRNA levels and the NF-E2-related factor 2 (NRF2) protein Level, and inflammation, as assessed by Tumor Necrosis Factor-α (TNF-α) and interleukin-6 mRNA levels and the NF-kB P65 protein level [21]. Zhang et al. [22] showed that micro-vessel density (MVD) and vascular endothelial growth factor (VEGF) were significantly higher in tumor from IH animal than control group. Treatment with endostatin attenuated serum and tissue VEGF levels, lowering the MVD values. This study indicated that IH might accelerate tumor growth by facilitating the angiogenesis in tumor tissue.

Our study revealed that OSA was not related with presence of pulmonary nodule or ≥ 6 mm pulmonary nodule in LDCT. In general, patients with ≥ 6 mm pulmonary nodule are considered to be at high risk of lung cancer, so we choose this standard. This is contradictory to the conclusion from a study, which indicated that nocturnal hypoxemia was associated with presence of > 6 mm lung nodules on multivariate analysis adjusted for confounders (OR = 2.6) [11]. The differences in the results might due to the different patient group. We included a group of patients suspected for OSA. The study by Perez-Warnisher et al. [11] included a group of patients with age and smoking criteria fulfilling a high risk of lung cancer (age 55–75 years; pack-years > 30). We also found that nocturnal hypoxia was independently related to the elevated of serum CEA level after adjusting confounding factors. This is consistent with a previous study reporting that the AHI score and ODI score were positively associated with the CEA level in T2DM patients [23]. Oxidative stress and inflammation responses are supposed to play a role in the association between OSA and elevated CEA [23, 24]. The oxidative stress and inflammation responses induced by OSA trigger the transmission of oncogene signaling and lead to the development of cancer [21, 25]. In addition, A previous study supported a positive correlation between serum CEA levels and lipid peroxidation [26]. Serum CEA levels are not only increased in lung cancer but also increased in other types of cancer, such as colorectal cancer. Actually, an previous epidemiological study showed that OSA was associated with an increased risk of colorectal cancer [27]. Therefore, it cannot be excluded that OSA was associated with other type of cancer (e.g., colorectal cancer).

However, it is vital to note the limitations of this study. First of all, this is a cross-sectional study; therefore, the observed associations do not indicate cause–effect relationships. Second, the sample size of this study is relatively small compared to the sample size of the community-based cohort study. Third, histological findings of lung nodules were not obtained in this study. Fourth, an AHI of 15/h, but not 5/h, was chosen as the threshold for grouping OSA and non-OSA. However, this threshold has been used in many previous studies and is also a useful limit to detect patients who need continuous positive airway pressure therapy. Finally, serum CEA level can be affected by many diseases or factors. Other cancer type such as colorectal cancer might not be excluded due to lack of endoscopic or PET–CT examining.

In conclusion, OSA was independently related to the elevated of serum CEA level, but not with presence of pulmonary nodule or ≥ 6 mm pulmonary nodule in LDCT. Further well-designed longitudinal studies with pathology available are needed to identify the association between OSA and risk of lung cancer.

Funding This research was funded by National Natural Science Foundation of China (No. 81900088 and 81870074) and Natural Science Foundation of Fujian Province (2022J011474). The sponsor had no role in the design or conduct of this research.

Data availability The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interest All authors declare that they have no conflict of interest.

References

1. Kendzerska T, Leung RS, Hawker G, Tomlinson G, Gershon AS (2014) Obstructive sleep apnea and the prevalence and incidence of cancer. CMAJ Can Med Assoc J journal de l’Association medicale canadienne 186:985–992

2. Campos-Rodriguez F, Martinez-Garcia MA, Martinez M, Duran-Cantolla J, Pena Mde L, Masdeu MJ, Gonzalez M, Campo F, Gallego I, Marin JM, Barbe F, Montserrat JM, Farre R (2013) Association between obstructive sleep apnea and cancer incidence in a large multicenter Spanish cohort. Am J Respir Crit Care Med 187:99–105

3. Nieto FJ, Peppard PE, Young T, Finn L, Hera KM, Farre R (2012) Sleep-disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med 186:190–194

4. Santamaria-Martos F, Benitez J, Giron C, Barbe F, Martinez-Garcia MA, Hernandez L, Montserrat JM, Nagore E, Martorell A, Campos-Rodriguez F, Corral J, Cabriada V, Abad J, Mediano O, Troncoso MF, Cano-Pumarega I, Fortuna Gutierrez AM, Diaz-Cambrilles T, Somoza-Gonzalez M, Almendros I, Farre R, Gozal D, Sanchez-de-la-Torre M, Spanish Sleep N (2018) Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea. Eur Respir J 51:1701885

5. Zhang XB, Peng LH, Lyu Z, Jiang XT, Du YP (2017) Obstructive sleep apnoea and the incidence and mortality of cancer: a meta-analysis. Eur J Cancer Care 26:e12427

6. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

7. Seijo LM, Perez-Warnisher MT, Giraldo-Cadavid LF, Oliveros H, Cabez M, Troncoso MF, Gomez T, Bellorin RJ, Echevarria ML, Gotera C, Perez-Rodriguez P, Gonzalez-Mangado N, Peces-Barba G (2019) Obstructive sleep apnea and nocturnal hypoxemia
are associated with an increased risk of lung cancer. Sleep Med 63:41–45
8. Huang HY, Lin SW, Chuang LP, Wang CL, Sun MH, Li HY, Chang CJ, Chang SC, Yang CT, Chen NH (2020) Severe OSA associated with higher risk of mortality in stage III and IV lung cancer. J Clin Sleep Med 16:1091–1098
9. Cabezas E, Perez-Warnisher MT, Troncoso MF, Gomez T, Melchor R, Pinillos EJ, El Hachem A, Gotera C, Rodriguez P, Mahillo Fernandez I, Martinez-Garcia MA, Peces-Barba G, Seijo LM (2019) Sleep disordered breathing is highly prevalent in patients with lung cancer: results of the apexa in lung cancer study. Respir Int Rev Thorac Dis 97:119–124
10. Liu Y, Lao M, Chen J, Lu M, Luo S, Ou Q, Luo Z, Yuan P, Chen J, Ye G, Gao X (2020) Short-term prognostic effects of circulating regulatory T-Cell suppressive function and vascular endothelial growth factor level in patients with non-small cell lung cancer and obstructive sleep apnea. Sleep Med 70:88–96
11. Perez-Warnisher MT, Cabezas E, Troncoso MF, Gomez T, Melchor R, Pinillos EJ, El Hachem A, Gotera C, Rodriguez P, Mahillo I, Gonzalez-Mangado N, Peces-Barba G, Seijo LM (2019) Sleep disordered breathing and nocturnal hypoxemia are very prevalent in a lung cancer screening population and may condition lung cancer screening findings: results of the prospective Sleep Apnea In Lung Cancer Screening (SAILS) study. Sleep Med 54:181–186
12. Dreher M, Kruger S, Schulze-Olden S, Keszen A, Storre JH, Woehrle H, Arzt M, Muller T (2018) Sleep-disordered breathing in patients with newly diagnosed lung cancer. BMC Pulm Med 18:72
13. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatzonis C, Marcus PM, Sicks JD (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409
14. Schulz H (2007) Phasic or transient? Comment on the terminology of the AASM manual for the scoring of sleep and associated events. J Clin sleep Med 3:752
15. Lin QC, Chen LD, Chen GP, Zhao JM, Chen X, Huang JF, Wu LH (2015) Association between nocturnal hypoxia and liver injury in the setting of nonalcoholic fatty liver disease. Sleep Breath Schlaf & Atmung 19:273–280
16. Polotsky VY, Patil SP, Savransky V, Laffan A, Fonti S, Frame LA, Steele KE, Schweitzer MA, Clark JM, Torgerson MS, Schwartz AR (2009) Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med 179:228–234
17. Ross SD, Sheinhait IA, Harrison KJ, Kvasz M, Connelly JE, Shea SA, Allen IE (2000) Systematic review and meta-analysis of the literature regarding the diagnosis of sleep apnea. Sleep 23:519–532
18. Marshall NS, Wong KK, Cullen SR, Knuiman MW, Grunstein RR (2014) Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort. J Clin Sleep Med 10:355–362
19. Huang T, Lin BM, Stamper MJ, Schnrenhammer ES, Saxena R, Trouroger SS, Redline S (2021) Associations of self-reported obstructive sleep apnea with total and site-specific cancer risk in older women: a prospective study. Sleep 44:zsaa198
20. Almendros I, Wang Y, Becker L, Lennon FE, Zheng J, Coats BR, Schoenfelt KS, Carreras A, Hakim F, Zhang SX, Farre R, Gozal D (2014) Intermittent hypoxia-induced changes in tumor-associated macrophages and tumor malignancy in a mouse model of sleep apnea. Am J Respir Crit Care Med 189:593–601
21. Li L, Ren F, Qi C, Xu L, Fang Y, Liang M, Feng J, Chen B, Ning W, Cao J (2018) Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. Respir Res 19:28
22. Zhang XB, Yang YY, Zeng Y, Zeng HQ, Fu BB, Ko CY, Luo X, Du YP, Chen LD, Lai YT, Wu Y (2019) Anti-tumor effect of endostatin in a sleep-apnea mouse model with tumor. Clin Transl Oncol 21:572–581
23. Zhou J, Huang X, Jiang X (2019) Effects of Obstructive sleep apnea-hypopnea syndrome on serum carcinoembryonic antigen levels in patients with type 2 diabetes mellitus. Med Sci Monit 25:3558–3565
24. Maniaci A, Iannella G, Cocuzza S, Vicini C, Magliulo G, Ferlito S, Cammaroto G, Meccariello G, De Vito A, Nicolai A, Pace A, Artico M, Taurone S (2021) Oxidative stress and inflammation biomarker expression in obstructive sleep apnea patients. J Clin Med 10:277
25. Andrisic L, Dudzik D, Barbas C, Milkovic L, Grune T, Zarkovic N (2018) Short overview on metabolomics approach to study pathophysiology of oxidative stress in cancer. Redox Biol 14:47–58
26. Hasan M, Mohieldeen A (2015) Association between serum carcinoembryonic antigen level and oxidative stress parameters among diabetic females. Int J Exp Med 8:6489–6494
27. Chen CY, Hu JM, Shen CJ, Chou YC, Tian YF, Chen YC, You SL, Hung CF, Lin TC, Hsiao CW, Lin CY, Sun CA (2020) Increased incidence of colorectal cancer with obstructive sleep apnea: a nationwide population-based cohort study. Sleep Med 66:15–20

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.